Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 664

1.

Obligatory Metabolism of Angiotensin II to Angiotensin III for Zona Glomerulosa Cell-Mediated Relaxations of Bovine Adrenal Cortical Arteries.

Kopf PG, Park SK, Herrnreiter A, Krause C, Roques BP, Campbell WB.

Endocrinology. 2018 Jan 1;159(1):238-247. doi: 10.1210/en.2017-00759.

2.

Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.

González-Rodríguez S, Poras H, Menéndez L, Lastra A, Ouimet T, Fournié-Zaluski MC, Roques BP, Baamonde A.

Scand J Pain. 2017 Jan;14:25-38. doi: 10.1016/j.sjpain.2016.09.011. Epub 2016 Nov 1.

PMID:
28850427
3.

Substituted α-mercaptoketones, new types of specific neprilysin inhibitors.

Poras H, Patouret R, Leiris S, Ouimet T, Fournié-Zaluski MC, Roques BP.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3883-3890. doi: 10.1016/j.bmcl.2017.06.050. Epub 2017 Jun 21.

PMID:
28676269
4.

Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.

Roques BP.

Handb Exp Pharmacol. 2018;247:53-70. doi: 10.1007/164_2016_17. Review.

PMID:
27417433
5.

Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain.

Bonnard E, Poras H, Fournié-Zaluski MC, Roques BP.

Eur J Pharmacol. 2016 Oct 5;788:176-182. doi: 10.1016/j.ejphar.2016.05.041. Epub 2016 Jun 4.

PMID:
27266667
6.

Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.

Poras H, Bonnard E, Fournié-Zaluski MC, Roques BP.

Eur J Med Chem. 2015 Sep 18;102:58-67. doi: 10.1016/j.ejmech.2015.07.027. Epub 2015 Jul 17.

PMID:
26241877
7.

Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain.

Bonnard E, Poras H, Nadal X, Maldonado R, Fournié-Zaluski MC, Roques BP.

Pharmacol Res Perspect. 2015 Mar;3(2):e00116. doi: 10.1002/prp2.116. Epub 2015 Jan 30.

8.

New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.

Poras H, Bonnard E, Dangé E, Fournié-Zaluski MC, Roques BP.

J Med Chem. 2014 Jul 10;57(13):5748-63. doi: 10.1021/jm500602h. Epub 2014 Jun 24.

PMID:
24927250
9.

TGF-β and opioid receptor signaling crosstalk results in improvement of endogenous and exogenous opioid analgesia under pathological pain conditions.

Lantero A, Tramullas M, Pílar-Cuellar F, Valdizán E, Santillán R, Roques BP, Hurlé MA.

J Neurosci. 2014 Apr 9;34(15):5385-95. doi: 10.1523/JNEUROSCI.4405-13.2014.

10.

Cocaine dysregulates opioid gating of GABA neurotransmission in the ventral pallidum.

Kupchik YM, Scofield MD, Rice KC, Cheng K, Roques BP, Kalivas PW.

J Neurosci. 2014 Jan 15;34(3):1057-66. doi: 10.1523/JNEUROSCI.4336-13.2014.

11.

Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques BP, Llorens-Cortes C.

Clin Pharmacokinet. 2014 Apr;53(4):385-95. doi: 10.1007/s40262-013-0125-y.

PMID:
24337978
12.

A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.

Poras H, Duquesnoy S, Fournié-Zaluski MC, Ratinaud-Giraud C, Roques BP, Ouimet T.

Anal Biochem. 2013 Oct 15;441(2):152-61. doi: 10.1016/j.ab.2013.06.016. Epub 2013 Jul 11.

PMID:
23851339
13.

Comparison of fluorigenic peptide substrates PL50, SNAPTide, and BoTest A/E for BoNT/A detection and quantification: exosite binding confers high-assay sensitivity.

Ouimet T, Duquesnoy S, Poras H, Fournié-Zaluski MC, Roques BP.

J Biomol Screen. 2013 Jul;18(6):726-35. doi: 10.1177/1087057113476089. Epub 2013 Feb 20. Erratum in: J Biomol Screen. 2014 Sep;19(8):1231.

PMID:
23427044
14.

Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue.

Schreiter A, Gore C, Labuz D, Fournie-Zaluski MC, Roques BP, Stein C, Machelska H.

FASEB J. 2012 Dec;26(12):5161-71. doi: 10.1096/fj.12-208678. Epub 2012 Aug 24.

PMID:
22923332
15.

Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.

Marc Y, Gao J, Balavoine F, Michaud A, Roques BP, Llorens-Cortes C.

Hypertension. 2012 Aug;60(2):411-8. doi: 10.1161/HYPERTENSIONAHA.112.190942. Epub 2012 Jun 18.

PMID:
22710644
16.

[New painkillers inhibiting the physiological breakdown of endogenous opioids].

Roques BP, Fournié-Zaluski MC, Wurm M.

Med Sci (Paris). 2012 May;28(5):476-8. doi: 10.1051/medsci/2012285011. Epub 2012 May 30. French. No abstract available.

17.

Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Roques BP, Fournié-Zaluski MC, Wurm M.

Nat Rev Drug Discov. 2012 Apr;11(4):292-310. doi: 10.1038/nrd3673. Review.

PMID:
22460123
18.

Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging.

Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaître M, Duquesnoy S, Garot J, Roques BP, Michel JB, Corot C, Ballet S.

Mol Pharm. 2012 Apr 2;9(4):850-61. doi: 10.1021/mp2003863. Epub 2012 Mar 8.

PMID:
22352457
19.

Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine.

Jutkiewicz EM, Roques BP.

Neuropsychopharmacology. 2012 Jan;37(1):303-4. doi: 10.1038/npp.2011.244. No abstract available.

20.

Pluripotentialities of a quenched fluorescent peptide substrate library: enzymatic detection, characterization, and isoenzymes differentiation.

Poras H, Ouimet T, Orng SV, Dangé E, Fournié-Zaluski MC, Roques BP.

Anal Biochem. 2011 Dec 15;419(2):95-105. doi: 10.1016/j.ab.2011.08.016. Epub 2011 Aug 16.

PMID:
21893023
21.

Relationship between vulnerability to reinforcing effects of morphine and activity of the endogenous cholecystokinin system in Lewis and Fischer rats.

Noble F, Benturquia N, Crete D, Canestrelli C, Mas Nieto M, Wilson J, Roques BP.

Addict Biol. 2012 May;17(3):528-38. doi: 10.1111/j.1369-1600.2010.00283.x. Epub 2011 Feb 11.

PMID:
21309946
22.

Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.

Ouimet T, Orng SV, Poras H, Gagnidze K, Devi LA, Fournié-Zaluski MC, Roques BP.

J Biol Chem. 2010 Nov 5;285(45):34390-400. doi: 10.1074/jbc.M110.120576. Epub 2010 Aug 31.

23.

Crystal structure of leukotriene A4 hydrolase in complex with kelatorphan, implications for design of zinc metallopeptidase inhibitors.

Tholander F, Roques BP, Fournié-Zaluski MC, Thunnissen MM, Haeggström JZ.

FEBS Lett. 2010 Aug 4;584(15):3446-51. doi: 10.1016/j.febslet.2010.06.044. Epub 2010 Jul 4.

24.

Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats.

Padia SH, Howell NL, Kemp BA, Fournie-Zaluski MC, Roques BP, Carey RM.

Hypertension. 2010 Feb;55(2):474-80. doi: 10.1161/HYPERTENSIONAHA.109.144956. Epub 2009 Dec 7.

25.

Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors.

González-Rodríguez S, Pevida M, Roques BP, Fournié-Zaluski MC, Hidalgo A, Menéndez L, Baamonde A.

Neurosci Lett. 2009 Nov 20;465(3):285-9. doi: 10.1016/j.neulet.2009.09.015. Epub 2009 Sep 16.

PMID:
19765404
26.

Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250.

Fournié-Zaluski MC, Poras H, Roques BP, Nakajima Y, Ito K, Yoshimoto T.

Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):814-22. doi: 10.1107/S090744490901779X. Epub 2009 Jul 17.

PMID:
19622865
27.

Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay.

Poras H, Ouimet T, Orng SV, Fournié-Zaluski MC, Popoff MR, Roques BP.

Appl Environ Microbiol. 2009 Jul;75(13):4382-90. doi: 10.1128/AEM.00091-09. Epub 2009 May 8.

28.

Structure-function relationship of Vpr: biological implications.

Morellet N, Roques BP, Bouaziz S.

Curr HIV Res. 2009 Mar;7(2):184-210. Review.

PMID:
19275588
29.

The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins.

Cabañero D, Célérier E, García-Nogales P, Mata M, Roques BP, Maldonado R, Puig MM.

Pain. 2009 Jan;141(1-2):88-96. doi: 10.1016/j.pain.2008.10.011. Epub 2008 Dec 5.

PMID:
19058913
30.

Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design.

Tholander F, Muroya A, Roques BP, Fournié-Zaluski MC, Thunnissen MM, Haeggström JZ.

Chem Biol. 2008 Sep 22;15(9):920-9. doi: 10.1016/j.chembiol.2008.07.018.

31.

How the HIV-1 nucleocapsid protein binds and destabilises the (-)primer binding site during reverse transcription.

Bourbigot S, Ramalanjaona N, Boudier C, Salgado GF, Roques BP, Mély Y, Bouaziz S, Morellet N.

J Mol Biol. 2008 Nov 28;383(5):1112-28. doi: 10.1016/j.jmb.2008.08.046. Epub 2008 Aug 26.

PMID:
18773912
32.

Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.

Menéndez L, Hidalgo A, Meana A, Poras H, Fournié-Zaluski MC, Roques BP, Baamonde A.

Eur J Pharmacol. 2008 Oct 31;596(1-3):50-5. doi: 10.1016/j.ejphar.2008.07.043. Epub 2008 Jul 30.

PMID:
18692494
33.

Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei.

de Mota N, Iturrioz X, Claperon C, Bodineau L, Fassot C, Roques BP, Palkovits M, Llorens-Cortes C.

J Neurochem. 2008 Jul;106(1):416-28. doi: 10.1111/j.1471-4159.2008.05402.x. Epub 2008 Apr 1.

34.

Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.

Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, Kim B, Bambara RA.

J Biol Chem. 2008 Apr 4;283(14):9196-205. doi: 10.1074/jbc.M710148200. Epub 2008 Jan 24.

35.

Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats.

Padia SH, Kemp BA, Howell NL, Fournie-Zaluski MC, Roques BP, Carey RM.

Hypertension. 2008 Feb;51(2):460-5. Epub 2007 Dec 24.

PMID:
18158338
36.

Proximity and branch migration mechanisms in HIV-1 minus strand strong stop DNA transfer.

Song M, Basu VP, Hanson MN, Roques BP, Bambara RA.

J Biol Chem. 2008 Feb 8;283(6):3141-50. Epub 2007 Dec 11.

37.

Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.

Noble F, Benturquia N, Bilkei-Gorzo A, Zimmer A, Roques BP.

Psychopharmacology (Berl). 2008 Feb;196(2):327-35. Epub 2007 Oct 1.

PMID:
17906961
38.

Specific blockade of morphine- and cocaine-induced reinforcing effects in conditioned place preference by nitrous oxide in mice.

Benturquia N, Le Guen S, Canestrelli C, Lagente V, Apiou G, Roques BP, Noble F.

Neuroscience. 2007 Nov 9;149(3):477-86. Epub 2007 Aug 8.

39.

Molecular mimicry in inducing DNA damage between HIV-1 Vpr and the anticancer agent, cisplatin.

Siddiqui K, Del Valle L, Morellet N, Cui J, Ghafouri M, Mukerjee R, Urbanska K, Fan S, Pattillo CB, Deshmane SL, Kiani MF, Ansari R, Khalili K, Roques BP, Reiss K, Bouaziz S, Amini S, Srinivasan A, Sawaya BE.

Oncogene. 2008 Jan 3;27(1):32-43. Epub 2007 Jul 23.

PMID:
17653096
40.

Molecular mechanism of the Zn2+-induced folding of the distal CCHC finger motif of the HIV-1 nucleocapsid protein.

Bombarda E, Grell E, Roques BP, Mély Y.

Biophys J. 2007 Jul 1;93(1):208-17. Epub 2007 Apr 6.

41.

Preproenkephalin knockout mice show no depression-related phenotype.

Bilkei-Gorzo A, Michel K, Noble F, Roques BP, Zimmer A.

Neuropsychopharmacology. 2007 Nov;32(11):2330-7. Epub 2007 Mar 21.

42.
43.

Mechanisms that prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages.

Purohit V, Roques BP, Kim B, Bambara RA.

J Biol Chem. 2007 Apr 27;282(17):12598-609. Epub 2007 Mar 2.

44.

Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs.

Noble F, Roques BP.

Expert Opin Ther Targets. 2007 Feb;11(2):145-59. Review.

PMID:
17227231
45.

Insights into the multiple roles of pausing in HIV-1 reverse transcriptase-promoted strand transfers.

Gao L, Balakrishnan M, Roques BP, Bambara RA.

J Biol Chem. 2007 Mar 2;282(9):6222-31. Epub 2007 Jan 3.

46.

Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats.

Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, Roques BP, Carey RM.

Hypertension. 2007 Mar;49(3):625-30. Epub 2006 Dec 26.

PMID:
17190872
47.

Sensitization to the conditioned rewarding effects of morphine modulates gene expression in rat hippocampus.

Marie-Claire C, Courtin C, Robert A, Gidrol X, Roques BP, Noble F.

Neuropharmacology. 2007 Feb;52(2):430-5. Epub 2006 Oct 2.

48.

Evidence that creation of invasion sites determines the rate of strand transfer mediated by HIV-1 reverse transcriptase.

Hanson MN, Balakrishnan M, Roques BP, Bambara RA.

J Mol Biol. 2006 Nov 10;363(5):878-90. Epub 2006 Aug 30.

PMID:
16997325
49.

Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice.

Jardinaud F, Roques BP, Noble F.

Behav Brain Res. 2006 Oct 16;173(2):255-61. Epub 2006 Aug 1.

PMID:
16884789
50.

Development and characterization of ten monoclonal anti-Vpr antibodies.

Sabbah EN, Delaunay T, Varin A, Le-Rouzic E, Benichou S, Herbein G, Druillennec S, Roques BP.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):630-9.

PMID:
16831087

Supplemental Content

Loading ...
Support Center